Abnormal T regulatory cells (Tregs: FOXP3+, CTLA-4+), myeloid-derived suppressor cells (MDSCs: Monocytic, granulocytic) and polarised T helper cell profiles (Th1, Th2, Th17) in women with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC) and surgery: Failure of abolition of abnormal treg profile with treatment and correlation of treg levels w

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Verma, Chandan ^a   Eremin, Jennifer M ^b   Robins, Adrian ^c   Bennett, Andrew J ^d   Cowley, Gerard P ^b   El Sheemy, Mohamed A ^b,e   Jibril, Jibril A ^b   Eremin, Oleg ^a,b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b LINCOLN COUNTY HOSPITAL   (United Kingdom)

^c QUEEN S MEDICAL CENTRE   (United Kingdom)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^e UNIVERSITY OF LINCOLN   (United Kingdom)

Author keywords

Breast cancer; Chemotherapy and surgery; Cytokines; Myeloid derived suppressor cells; Tregs

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DOCETAXEL; DOXORUBICIN; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; MESSENGER RNA; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CELLULAR IMMUNITY; CONTROLLED STUDY; CTLA 4 GENE; CYTOKINE PRODUCTION; DRUG RESPONSE; FEMALE; FOXP3 GENE; GENE; GENE EXPRESSION; GRANULOCYTE; HELPER CELL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE DYSREGULATION; IN VITRO STUDY; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MASTECTOMY; MONOCYTE; MULTIPLE CYCLE TREATMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUPPRESSOR CELL; TH1 CELL; TH17 CELL; TH2 CELL; TREATMENT OUTCOME;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CTLA-4 ANTIGEN; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAGNETIC RESONANCE IMAGING; MAMMOGRAPHY; NEOADJUVANT THERAPY; PHENOTYPE; RNA, MESSENGER; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH17 CELLS; TH2 CELLS;

EID: 84875919484     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-16     Document Type: Article

References (57)

1. Shankaran V. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001, 410(6832):1107-1111. 10.1038/35074122, 11323675.
2. Street SE. Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and gammadelta T cells. J Exp Med 2004, 199(6):879-884. 10.1084/jem.20031981, 2212720, 15007091.
3. Langowski JL. IL-23 promotes tumour incidence and growth. Nature 2006, 442(7101):461-465. 10.1038/nature04808, 16688182.
4. Aloysius M, Walker L, Eremin O. Cancer and the immune response, Ch 4. Essential immunology for surgeons 2011, 236-300. Oxford: OUP, Eremin O, Sewell H.
5. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004, 22:329-360. 10.1146/annurev.immunol.22.012703.104803, 15032581.
6. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006, 6(1):24-37. 10.1038/nrc1782, 16397525.
7. Gallina G. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest 2006, 116(10):2777-2790. 10.1172/JCI28828, 1578632, 17016559.
8. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012, 12(4):253-268. 10.1038/nri3175, 3587148, 22437938.
9. Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010, 22(2):231-237. 10.1016/j.coi.2010.01.009, 20144856.
10. Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer 2010, 127(4):759-767.
11. Liyanage UK. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002, 169(5):2756-2761.
12. Viguier M. Foxp3 expressing CD4 + CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004, 173(2):1444-1453.
13. Kawaida H. Distribution of CD4 + CD25high regulatory T-cells in tumor-draining lymph nodes in patients with gastric cancer. J Surg Res 2005, 124(1):151-157. 10.1016/j.jss.2004.10.004, 15734494.
14. Miller AM. CD4 + CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 2006, 177(10):7398-7405.
15. Vasievich EA, Huang L. The suppressive tumor microenvironment: a challenge in cancer immunotherapy. Mol Pharm 2011, 8(3):635-641. 10.1021/mp1004228, 21545153.
16. Curiel TJ. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004, 10(9):942-949. 10.1038/nm1093, 15322536.
17. Walunas TL, Bakker CY, Bluestone JA. CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med 1996, 183(6):2541-2550. 10.1084/jem.183.6.2541, 2192609, 8676075.
18. Greenwald RJ. CTLA-4 regulates cell cycle progression during a primary immune response. Eur J Immunol 2002, 32(2):366-373. 10.1002/1521-4141(200202)32:2<366::AID-IMMU366>3.0.CO;2-5, 11807776.
19. Talmadge JE, Donkor M, Scholar E. Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metastasis Rev 2007, 26(3-4):373-400.
20. Peranzoni E. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol 2010, 22(2):238-244. 10.1016/j.coi.2010.01.021, 20171075.
21. Bierie B, Moses HL. Transforming growth factor beta (TGF-beta) and inflammation in cancer. Cytokine Growth Factor Rev 2010, 21(1):49-59. 10.1016/j.cytogfr.2009.11.008, 2834863, 20018551.
22. Huang B. Gr-1 + CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 2006, 66(2):1123-1131. 10.1158/0008-5472.CAN-05-1299, 16424049.
23. Zitvogel L. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008, 8(1):59-73. 10.1038/nri2216, 18097448.
24. Liu WM. Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br J Cancer 2010, 102(1):115-123. 10.1038/sj.bjc.6605465, 2813751, 19997099.
25. Aloysius M, Verma C, Eremin O. Therapy and Host Defences Ch 7. Essential Immunology for Surgeons 2011, 379-402. Oxford: OUP, Eremin O, Sewell H.
26. Zitvogel L. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res 2010, 16(12):3100-3104. 10.1158/1078-0432.CCR-09-2891, 20421432.
27. Tsavaris N. Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer 2002, 87(1):21-27. 10.1038/sj.bjc.6600347, 2364288, 12085250.
28. Pusztai L. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 2004, 25(3):94-102. 10.1016/j.cyto.2003.10.004, 14698135.
29. Ghiringhelli F. CD4 + CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004, 34(2):336-344. 10.1002/eji.200324181, 14768038.
30. Lutsiak ME. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005, 105(7):2862-2868. 10.1182/blood-2004-06-2410, 15591121.
31. Smith IC. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002, 20(6):1456-1466. 10.1200/JCO.20.6.1456, 11896092.
32. Walker L. Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: a randomised study of sequential weekly versus three-weekly docetaxel following neoadjuvant doxorubicin and cyclophosphamide in women with primary breast cancer. BMC Cancer 2011, 18(11):179.
33. Baxevanis CN, Perez SA, Papamichail M. Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy. Cancer Immunol Immunother 2009, 58(3):317-324. 10.1007/s00262-008-0576-4, 18704409.
34. Sinha P. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 2007, 67(9):4507-4513. 10.1158/0008-5472.CAN-06-4174, 17483367.
35. Diaz-Montero CM. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 2009, 58(1):49-59. 10.1007/s00262-008-0523-4, 3401888, 18446337.
36. Aruga T. A low number of tumor-infiltrating FOXP3-positive cells during primary systemic chemotherapy correlates with favorable anti-tumor response in patients with breast cancer. Oncol Rep 2009, 22(2):273-278.
37. Jaberipour M. Increased CTLA-4 and FOXP3 transcripts in peripheral blood mononuclear cells of patients with breast cancer. Pathol Oncol Res 2010, 16(4):547-551. 10.1007/s12253-010-9256-8, 20306312.
38. Rech AJ. Homeostasis of peripheral FoxP3(+) CD4 (+) regulatory T cells in patients with early and late stage breast cancer. Cancer Immunol Immunother 2010, 59(4):599-607. 10.1007/s00262-009-0780-x, 19855964.
39. Audia S. Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes. Clin Exp Immunol 2007, 150(3):523-530. 10.1111/j.1365-2249.2007.03521.x, 2219383, 17956583.
40. Mansfield AS. Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancer. BMC Cancer 2009, 9:231. 10.1186/1471-2407-9-231, 2723126, 19604349.
41. Liu F. CD8(+) cytotoxic T cell and FOXP3(+) regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes. Breast Cancer Res Treat 2011, 130(2):645-655. 10.1007/s10549-011-1647-3, 21717105.
42. Liu SV. Neoadjuvant therapy for breast cancer. J Surg Oncol 2010, 101(4):283-291. 10.1002/jso.21446, 20187061.
43. Ladoire S. Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells. Clin Cancer Res 2008, 14(8):2413-2420. 10.1158/1078-0432.CCR-07-4491, 18413832.
44. Oda N, Shimazu K. Intratumoral regulatory T cells as an independent predictive factor for pathological complete response to neoadjuvant paclitaxel followed by 5-FU/epirubicin/cyclophosphamide in breast cancer patients. Breast Cancer Res Treat 2012, 136(1):107-116. 10.1007/s10549-012-2245-8, 22986814.
45. Bates GJ, Fox SB. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006, 24(34):5373-5380. 10.1200/JCO.2006.05.9584, 17135638.
46. Ghebeh H, Barhoush E. FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. BMC Cancer 2008, 8:5. 10.1186/1471-2407-8-5, 2249586, 18194510.
47. Merlo A, Casalini P. FOXP3 expression and overall survival in breast cancer. J Clin Oncol 2009, 27(11):1746-1752. 10.1200/JCO.2008.17.9036, 19255331.
48. Lee S, Cho EY. Prognostic impact of FOXP3 expression in triple-negative breast cancer. Acta Oncol 2013, 52(1):73-8149. 10.3109/0284186X.2012.731520, 23075422.
49. Liu CY. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14(-)/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol 2010, 136(1):35-45. 10.1007/s00432-009-0634-0, 19572148.
50. Hoechst B. Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells. Blood 2011, 117(24):6532-6541. 10.1182/blood-2010-11-317321, 21493801.
51. DeNardo DG, Coussens LM. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res 2007, 9(4):212. 10.1186/bcr1746, 2206719, 17705880.
52. Ji Y, Zhang W. Th17 cells: positive or negative role in tumor?. Cancer Immunol Immunother 2010, 59(7):979-987. 10.1007/s00262-010-0849-6, 20352428.
53. Kryczek I. Human TH17 cells are long-lived effector memory cells. Sci Transl Med 2011, 3(104):104ra100. 10.1126/scitranslmed.3002949, 3345568, 21998407.
54. Muranski P. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008, 112(2):362-373. 10.1182/blood-2007-11-120998, 2442746, 18354038.
55. Martin-Orozco N. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 2009, 31(5):787-798. 10.1016/j.immuni.2009.09.014, 2787786, 19879162.
56. Yang L. Expression of Th17 cells in breast cancer tissue and its association with clinical parameters. Cell Biochem Biophys 2012, 62(1):153-159. 10.1007/s12013-011-9276-3, 22081436.
57. Viaud S. Cyclophosphamide induces differentiation of Th17 cells in cancer patients. Cancer Res 2011, 71(3):661-665. 10.1158/0008-5472.CAN-10-1259, 21148486.